Medtronic’s VenaSeal Spectrum postmarket clinical trial program is highlighting the need for further patient-centric ...

For patients with venous ulcers (CEAP C6 patients), ulcer area was reduced a median average of eighty-seven percent (87%). Over the course of the 1-year period, there was one (1) death (unrelated ...